11/5/2026

speaker
Conference Operator
Operator

Welcome to Inogen's third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star followed by one on your touch-tone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this conference is being recorded today, November 20th. As a reminder, this conference is being recorded today, November 5th, 2026. And now, I would like to turn the call over to Lorna Williams, Senior Vice President of Investor Relations and Strategic Planning.

speaker
Lorna Williams
Senior Vice President of Investor Relations and Strategic Planning

Thank you all for participating in today's call. Joining me are President and Chief Executive Officer Andy Redding and Chief Financial Officer Jason Richardson. Earlier today, Inogen released financial results for the third quarter of 2026. The earnings release is available in the investor relations section of the company's website along with the supplemental financial package. During today's call, we will be discussing non-GAAP financial measures that we believe will provide useful information for investors. The information is not intended to be considered in isolation or as a substitute for GAAP financial information. Reconciliations for these non-GAAP measures to the most directly comparable GAAP measures are included in today's earnings release and supplemental financial package, each of which is available in the investor relations section of our website. In addition, our discussion today will include forward-looking statements, including but not limited to the expectations about our future financial and operating performance. We make these statements based on current expectations and reasonable assumptions. However, our actual results could differ due to risks and uncertainties. Please review our annual report and other SEC filings for a discussion of risk factors that could cause our actual results to differ materially from any forward-looking statements made today. Forward-looking statements made on today's call speak only as of today, and Inogen undertakes no obligation to update or revise these statements except as required by law. The company has not provided a reconciliation of forward-looking adjusted earnings metrics to the most directly comparable gap measures because certain items that impact net income are uncertain or outside the company's control and cannot be reasonably predicted without unreasonable effort. With that, I will turn the call over to Inogen's president and CEO, Andy Reding.

speaker
Andy Redding
President and Chief Executive Officer

Thank you, Lorna. Good afternoon, everyone, and thank you for being with us for Inogen's third quarter 2026 earnings call. I'm pleased to speak to you today as Inogen's new CEO. Before I turn to the results, I'd like to share why I joined Indigen and why I'm excited about what lies ahead. I came to Indigen as Chief Operating Officer in July, after more than 30 years in medical technology, including a number of years in respiratory care. The common thread throughout my career has been growth, building commercial organizations, bringing new products to market, and scaling businesses that make a difference in the lives of patients. Most recently, I spent more than six years as Chief Commercial Officer of Viant Medical, where I led commercial teams as the company grew to 25 facilities and hundreds of medical device customers, including many of the industry's largest. Before that, as Vice President and General Manager of Hill-Rom Respiratory Health, I was responsible for sales, marketing, R&D, and reimbursement. These experiences shaped my approach to Inogen. I identified the opportunities with the greatest potential, align the organization around clear priorities and hold ourselves accountable for results. That is how I intend to lead. What drew me to Inogen was its important mission and significant untapped potential supported by a market leading core business, a differentiated portfolio, deep customer relationships, and talented associates. Over the past several months, I've spent time with our employees, customers, and distributors. I've seen numerous unsolicited emails from patients who praise our products and the support they receive from our associates. I've spoken to physicians and healthcare teams who state that patients ask for our product by name, and I've met with partners who appreciate the quality of our products. All of this feedback reinforces my conviction in the opportunity ahead. When I joined, My mandate was to improve commercial and operational performance, align priorities across the organization, and translate our strategy into efficient, measurable outcomes. The US oxygen rental business quickly emerged as an opportunity to streamline our operating model, sharpen our commercial focus, and strengthen our financial profile. We've now completed that divestiture. An important step toward a simpler Inogen that can direct its resources to where we are strongest. Importantly, US sales returned to year-over-year growth in the third quarter for the first time since the fourth quarter of 2024, driven by distributor demand and contributions from new products. We're on our way to creating a more focused organization and a stronger foundation. As CEO, I will build on that foundation. improve performance across the business, and turn our priorities into consistent, sustainable results. With that, I want to turn to our results for the quarter at a high level. Jason will share more detail shortly, but the headlines are as follows. Total revenue was $77.2 million, excluding the rental business. U.S. sales were $42.2 million, increasing 3.8% year over year, driven by distributor demand and new product contribution of approximately 250 basis points of growth. International sales were $34.9 million, decreasing 9%, driven by softness in capital spending of a few large European customers. Overall POC unit volume increased nearly 6% year over year to 51,900 units and increased 9.5% year to date. reflecting continued demand for our core products. Adjusted net loss from continuing operations was $0.4 million in the third quarter of 2026. And we announced an additional $20 million cost savings program to accelerate profitability. I want to be clear, these results are not where they need to be and we're taking action to improve them. In the near term, our work is centered on growing our commercial team and improving performance in our two channels, advancing the products that can drive growth and maintaining a rigorous focus on operating performance. Together, these priorities are intended to put Inogen on a stronger path towards sustainable growth and profitability. Over the next several months, I will continue spending time with customers, partners and associates, as well as engaging closely with our shareholders as we refine our priorities and transform Inogen. I look forward to speaking with many of you in the coming weeks. With that, Jason will take you through the results and the drivers behind them in more detail. Jason?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation